CCRB Logo

Trial Detail

CUHK_CCT00110

2006-03-27

Prospective

None

Nil

Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong

N/A

Jeffrey Wing Hong FUNG

Department of Medicine & Therapeutics, CUHK

852-2683-8525

jwhfung@cuhk.edu.hk

PWH

Jeffrey Wing Hong FUNG

Department of Medicine & Therapeutics, CUHK

852-2683-8525

jwhfung@cuhk.edu.hk

PWH

Effect of Theophylline to Prevent Contrast Induced Nephropathy in Patients With Renal Insufficiency

Effect of Theophylline to Prevent Contrast Induced Nephropathy in Patients With Renal Insufficiency

N/A

Hong Kong

Yes

2006-02-20

Coronary Heart Disease & Chronic Renal Insufficiency

Drug

Theophylline infusion in addition to N-acetylcysteine and saline hydration

once

No drug in addition to N-acetylcysteine and saline hydration

Inclusion: 1. Patient willing to sign informed consent form 2. Patient over 18 years of age 3. Patient undergoing coronary angiography or intervention 4. Patient with a serum creatinine 1.30 to 4.52 mg/dL (115 to 400 umol/l)

Exclusion: 1. Patient with known allergy to or have already taken N-acetylcysteine (Fluimucil), theophylline or contrast agents 2. Patinet is in acute renal failure (2 Cr level differ by 15% within 1 month) 3. Patient in cardiogenic shock 4. Patient with significant cardiac arrhythmia 5. Pregnant women 6. Patients with child bearing age without appropriate contraception 7. Current dialysis patient 8. Concomitant use of dopamine and mannitol

>18

N/A

Both Male and Female

Interventional

Randomized

Placebo

Open label

Parallel

2006-03-30

200

Unknown

Development of contrast nephropathy, defined as an increase in serum creatinine concentration of > and = 0.5 mg/dL, or a reduction in estimated glomerular filtration rate of > and = 25% of the baseline value, within 48 hours after the procedure

N/A

No

2011-04-01

ChiCTR-TRC-09000682

2010-05-04

Type Document Published On  
No documents yet.
  • Page 1 of 1.